Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 27,000 shares at $21.19 ($573K) on 2026-05-01, disclosed to the SEC on 2026-05-05.
Scheduled sale ($573k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.19 | 25,900 | $549K | 95.8% |
| 2 | $22.00 | 1,100 | $24K | 4.2% |
| Total | $21.23 avg | 27,000 | $573K | 100% |
| Filing → |
| TNGX | SELL | 2026-08-05 | $736K | — | Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |